Phytosomes, i.e., phospholipid complexes, are a vesicular drug delivery system engineered to enhance the biopharmaceutical and pharmacokinetics of poorly water-soluble phytoconstituents. However, the stickiness of the phytosomes causes their aggregation, showing low solubility and poor dissolution of phytoconstituents. Therefore, ferulic acid phytosomes (FAP) were prepared using Phospholipon80G (PL80G) and converted into solidified phytosomes (S-FAPs) using COS M-5P. S-FAPs were tested employing particle size, zeta potential, scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), powder x-ray diffractometry (PXRD), proton nuclear magnetic resonance (H-NMR), powder characteristics, solubility, and in vitro dissolution. S-FAPs enhanced the entrapment of FA ~ 82.08% within the polar head of phospholipids. The particle size ~ 335.96 nm, PDI ~ 0.20, and high zeta potential ~ -55.3 mV of S-FAPs suggest its suitability for the oral route. Physical analysis confirmed the synthesis of FAP and S-FAPs through weak intermolecular bonding among FA, PL80G and COS M-5P. Powder characteristics study indicated that S-FAPs improved the powder flow properties compared to FAPs. A solubility study indicated that S-FAPs drastically enhanced the solubility of FA (~ 2-fold) and FAPs (~ 1.5-fold) compared to pure FA. Likewise, S-FAPs and FAPs enhanced the dissolution by ~ 53% and ~ 39% compared to pure FA by ~ 25%. Pharmacokinetic results indicated that S-FAPs significantly enhanced the Cmax, Tmax, AUC and MRT compared to FAPs and pure FA, suggesting enhanced oral bioavailability of FA. A stability study suggested optimized S-FAPs are physically and chemically stable under different pH conditions. Findings indicate that developed S-FAPs using COS M-5P could be used as an anticipated formulation scheme to ameliorate FA's biopharmaceutical and pharmacokinetic properties.